EichorEICHOR
Study identifier: NCT07745374 Synced from ClinicalTrials.gov · August 09, 2026
● Study status: Recruiting

Safety and Feasibility of DBS for Bipolar Depression

Condition: Bipolar I Disorder · Bipolar Depression  ·  Sponsor: Icahn School of Medicine at Mount Sinai

PhaseNA
Planned participants5
Who can joinAll sexes, 22 Years to 70 Years
Healthy volunteersNoCheck eligibility criteria ↓
WhereNew York, New York, United States

Interested? Contact the study team ↓

For sponsors, CROs & site teams
Professional view of this study — listed sites, countries and recruiting context from the public registry. Everything below is written for patients and caregivers.See where this study is running →

About this study

This study addresses a critical unmet need in the treatment of bipolar disorder by investigating whether Subcallosal Cingulate (SCC) Deep Brain Stimulation (DBS) can safely and effectively treat treatment-resistant bipolar depression without inducing manic switches. The researchers propose to accomplish this by incorporating monitoring of the SCC local field potentials (LFP) for depression tracking and amygdala LFP monitoring for mania prediction while treating Bipolar I patients with SCC DBS Stimulation. This approach could establish a new paradigm for personalized neuromodulation therapy that uses real-time neural monitoring to optimize outcomes while minimizing risks. By incorporating bilateral, dual-site LFP monitoring from both the SCC and amygdala, this research will allow the researchers to assess the therapeutic efficacy of continuous SCC-DBS and develop novel safety biomarkers that could transform the clinical management of DBS therapy in psychiatry. The findings will have immediate implications for clinical practice and will advance the study team's fundamental understanding of the neural circuits underlying mood regulation and dysregulation in bipolar disorder.

This description comes directly from the study's public registry record.

Talk to the study team

Ellie Rapp  ·  646-493-1607  ·  ellie.rapp@mssm.edu

Avantika Vardhan  ·  avantika.vardhan@mssm.edu

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: * Age 22-70 years * Ability to provide written informed consent * Primary diagnosis of Bipolar I Disorder confirmed by SCID-5 * Current major depressive episode (MDE) of at least 12 months duration * Stable control of mania for a minimum of 1 year * Agreement to remain on current anti-mania medication regimen * Hamilton Depression Rating Scale-17 (HDRS-17) score ≥20 at screening and baseline * Young Mania Rating Scale (YMRS) score \<12 at screening and baseline * Treatment-resistant depression: failure to respond to at least 4 adequate trials of antidepressant treatment in the current episode. Antidepressant treatments include: Medications (Must include 2 antidepressant medications from different pharmacological classes), Psychotherapy, ECT, repetitive transcranial magnetic stimulation (rTMS), IV ketamine or intra-nasal esketamine. * All patients must be receiving at least one mood stabilizing medication at entry into the trial. Medication regimen must be stable for a minimum of 4 weeks before the baseline visit. * Able to provide informed consent * English-speaking * Deemed suitable surgical candidate by neurosurgical evaluation * Under care of treating psychiatrist willing to collaborate with study team * Able to reside in New York Metropolitan area during first 6 months or willing/able to travel monthly to study site * Provision of at least two emergency contacts age ≥22 residing within reasonable proximity Exclusion Criteria * Current manic or hypomanic episode (YMRS ≥12) * Rapid cycling pattern (≥4 mood episodes in the past 12 months) * Active suicidal ideation with intent or plan * Suicide attempt within six months prior to baseline * Current psychotic symptoms * Primary diagnosis of schizophrenia, schizoaffective disorder, or other psychotic disorder * History (current and/or lifetime) of one or more schizophrenia-spectrum or other psychotic disorders including: schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, and major depressive disorder with psychosis (unipolar or bipolar), and/or psychotic depression (unipolar or bipolar) (does not include psychosis occurring in the context of a manic episode of a subject with bipolar disorder) * Substance use disorder (moderate or severe) within 6 months * Presence of any type of dementia / Major Neurocognitive Disorder / significant cognitive impairment interfering with study participation * Subject has had a prior VNS Therapy or deep brain stimulation (DBS) implant * Subject has a diagnosis of Substance Use Disorder as defined by the DSM-V without sustained remission (12 months or longer) * History of borderline or severe personality disorder, as determined by clinical judgment, which would significantly interfere with a subject's participation in the study * Active primary diagnosis of one or more of the following disorders: obsessive-compulsive disorder, eating disorder, or post-traumatic stress disorder * Cognitive or psychiatric deficit (e.g., amnesia, delirium) that in the investigator's judgment would interfere with the subject's ability to accurately complete study assessments * Current or lifetime history of psychotic features in any major depressive episode (MDE) * Treatment with another investigational device or investigational drugs * Contraindications to MRI (metallic implants, claustrophobia unmanageable with anxiolytics) * Contraindications to general anesthesia or neurosurgery * Significant structural brain abnormalities precluding safe electrode placement * Active infection or immunocompromised state * Active unstable medial condition (diabetes, heart disease, hypertension, cancer, endocrine) * BMI \>35; and/or CRP \>3 * Coagulopathy or anticoagulation that cannot be safely interrupted * Pregnancy or planning pregnancy during study period * Women of childbearing potential unwilling to use effective contraception * Prisoners or institutionalized individuals * Decisionally impaired individuals (unless previously consented when capacitated) * Special status patients (employees, VIPs, celebrities, public figures) unless consented before special status known

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (1)

Center for Advanced Circuit Therapeutics, Clinical Neurosciences Center, Mount Sinai WestNew York, New York, United StatesRecruiting

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

New York

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →